Pregabalin for the treatment of cough

Pregabalin for the treatment of subacute and chronic refractory cough

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170215032587N5

Enrollment

Registered

2019-03-12

Start date

2019-03-21

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough. Cough

Interventions

Intervention 1: Intervention group: pregabalin capsule, oral, 150 mg, every 12 hours for two weeks. Intervention 2: Control group: placebo capsule, oral, every 12 hours for two weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Subacute cough (between 3 and 8 weeks) or chronic cough

Exclusion criteria

Exclusion criteria: History of asthma History of chronic bronchitis Pneumonia, pulmonary abscess or pulmonary tuberculosis Smokers

Design outcomes

Primary

Measure	Time frame
Number of cough attacks per day. Timepoint: 7 and 14 days after intervention. Method of measurement: Patient statement.;Number of coughs per attack. Timepoint: 7 and 14 days after intervention. Method of measurement: Patient statement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hasan Adeli

Ghoum University of Medical Sciences

Adeli@muq.ac.ir+98 25 3285 2720

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026